Immunoblot of tumor bulk protein and in situ immunohistochemistry indicated that MIR31HG ASO therapy downregulated expression of GLI2, ABCG2, and SOX2 (Fig. 6G, H, Fig. S10B, C). This evidence concerns the gene GLI2 and neoplasm.